Dantrolene sodium is a Small Molecule owned by Eagle Pharmaceuticals, and is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing.

Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1 and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction, thereby checks the underlying cause of disease progression.

The revenue for Dantrolene sodium is expected to reach a total of $508m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dantrolene sodium NPV Report.

Dantrolene sodium is currently owned by Eagle Pharmaceuticals.

Dantrolene sodium Overview

Dantrolene sodium (Ryanodex) is a hydantoin derivative acts as skeletal muscle relaxant. It is formulated as lyophilized powder for suspension administered through intravenous route. Ryanodex is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and prevention of malignant hyperthermia in patients at high risk.

Dantrolene sodium is under development for the treatment of acute radiation syndrome in hematopoietic syndrome patients exposed to high doses of radiation, exertional heat stroke, cerebral concussion and other forms of traumatic brain Injury and for nerve-agent induced brain damage, Alzheimer's disease and coronavirus infection (COVID-19).

It was under development for the treatment of psychostimulant drug-induced toxicity (MDMA and Methamphetamine Intoxication).

Eagle Pharmaceuticals Overview

Eagle Pharmaceuticals (Eagle), is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EGL-5385-C-1701 (fulvestrant) and Vasopressin injection for blood pressure. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.

The company reported revenues of (US Dollars) US$171.6 million for the fiscal year ended December 2021 (FY2021), a decrease of 8.7% over FY2020. In FY2021, the company’s operating margin was 1.6%, compared to an operating margin of 17.5% in FY2020. The net loss of the company was US$8.6 million in FY2021, compared to a net profit of US$12 million in FY2020. The company reported revenues of US$65.9 million for the third quarter ended September 2022, a decrease of 11.1% over the previous quarter.

Quick View – Dantrolene sodium

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Dantrolene sodium
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Infectious Disease
  • Other Diseases
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.